Countering the problem of falsified and substandard drugs /:
"The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a M...
Gespeichert in:
| Körperschaft: | |
|---|---|
| Weitere Verfasser: | , |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Washington, D.C. :
National Academies Press,
[2013]
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | "The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines"--Publisher's description. |
| Beschreibung: | 1 online resource (xxiv, 351 pages) : illustrations (chiefly color), color maps |
| Bibliographie: | Includes bibliographical references. |
| ISBN: | 9780309269407 0309269407 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn839275199 | ||
| 003 | OCoLC | ||
| 005 | 20240705115654.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 130408t20132013dcuab obt 000 0 eng d | ||
| 040 | |a COO |b eng |e rda |e pn |c COO |d GPM |d MMU |d AKU |d OCLCO |d OCLCA |d UCNAP |d CUS |d OCLCF |d OCLCO |d CUS |d VT2 |d E7B |d N$T |d YDXCP |d OCLCO |d OCLCQ |d OCLCO |d EBLCP |d OCLCO |d AGLDB |d MERUC |d OCLCQ |d ZCU |d OCLCA |d OCLCO |d OCLCA |d U3W |d OCLCA |d BUF |d OCLCO |d GILDS |d STF |d VNS |d OCLCO |d OCLCQ |d VTS |d EZ9 |d OCLCA |d ICG |d OCLCO |d CUY |d OCLCO |d REC |d OCLCO |d AU@ |d OCLCO |d OCLCQ |d WYU |d OCLCA |d LVT |d OCLCA |d S9I |d TKN |d DKC |d OCLCO |d OCLCQ |d OCLCO |d M8D |d OCLCO |d OCLCQ |d K6U |d OCLCA |d VLY |d OCLCO |d CUV |d VHC |d OCLCO |d OCLCQ |d OCL |d OCLCO |d UKAHL |d OCLCL |d OCLCQ |d UEJ |d OCLCO |d OCLCQ | ||
| 019 | |a 880439886 |a 880598095 |a 929505330 |a 932320631 |a 961541600 |a 962566672 |a 1013281256 |a 1021249589 |a 1028757444 |a 1048158507 |a 1055345724 |a 1066010422 |a 1081203238 |a 1142730752 |a 1156364339 |a 1162554800 |a 1176019756 |a 1225734707 |a 1228558864 |a 1229699560 |a 1241869177 |a 1249222552 |a 1290089510 |a 1300664907 |a 1303326026 |a 1303518494 | ||
| 020 | |a 9780309269407 | ||
| 020 | |a 0309269407 | ||
| 020 | |z 9780309269391 |q (paperback) | ||
| 020 | |z 0309269393 |q (paperback) | ||
| 035 | |a (OCoLC)839275199 |z (OCoLC)880439886 |z (OCoLC)880598095 |z (OCoLC)929505330 |z (OCoLC)932320631 |z (OCoLC)961541600 |z (OCoLC)962566672 |z (OCoLC)1013281256 |z (OCoLC)1021249589 |z (OCoLC)1028757444 |z (OCoLC)1048158507 |z (OCoLC)1055345724 |z (OCoLC)1066010422 |z (OCoLC)1081203238 |z (OCoLC)1142730752 |z (OCoLC)1156364339 |z (OCoLC)1162554800 |z (OCoLC)1176019756 |z (OCoLC)1225734707 |z (OCoLC)1228558864 |z (OCoLC)1229699560 |z (OCoLC)1241869177 |z (OCoLC)1249222552 |z (OCoLC)1290089510 |z (OCoLC)1300664907 |z (OCoLC)1303326026 |z (OCoLC)1303518494 | ||
| 050 | 4 | |a HD9665.5 |b .I578 2013 | |
| 060 | 4 | |a QV 773 | |
| 072 | 7 | |a BUS |x 070000 |2 bisacsh | |
| 082 | 7 | |a 338.4/76151 |2 23 | |
| 049 | |a MAIN | ||
| 110 | 2 | |a Institute of Medicine (U.S.). |b Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, |e author. |0 http://id.loc.gov/authorities/names/n2014180450 | |
| 245 | 1 | 0 | |a Countering the problem of falsified and substandard drugs / |c Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Board on Global Health ; Gillian J. Buckley and Lawrence O. Gostin, editors ; Institute of Medicine of the National Academies. |
| 264 | 1 | |a Washington, D.C. : |b National Academies Press, |c [2013] | |
| 264 | 4 | |c ©2013 | |
| 300 | |a 1 online resource (xxiv, 351 pages) : |b illustrations (chiefly color), color maps | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a data file |2 rda | ||
| 520 | |a "The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines"--Publisher's description. | ||
| 504 | |a Includes bibliographical references. | ||
| 505 | 0 | |a Introduction -- The effects of falsified and substandard drugs -- The magnitude of the problem -- Causes of falsified and substandard drugs -- Weaknesses in the drug distribution chain -- Detection technology -- An international code of practice for falsified and substandard medicines. | |
| 546 | |a English. | ||
| 536 | |a Supported by the National Academy of Sciences and the U.S. Food and Drug Administration |b HHSF22301024T |g 25 | ||
| 588 | 0 | |a Online resource; title from resource home page (National Academies Press, viewed June 12, 2013). | |
| 650 | 0 | |a Pharmaceutical industry. | |
| 650 | 0 | |a Pharmaceutical industry |x Quality control. | |
| 650 | 0 | |a Fraud |x Prevention. | |
| 650 | 0 | |a Quality control. |0 http://id.loc.gov/authorities/subjects/sh85109440 | |
| 650 | 0 | |a International cooperation. |0 http://id.loc.gov/authorities/subjects/sh85067385 | |
| 650 | 1 | 2 | |a Counterfeit Drugs |
| 650 | 1 | 2 | |a Fraud |x prevention & control |
| 650 | 2 | 2 | |a Drug Contamination |x prevention & control |
| 650 | 2 | 2 | |a Pharmaceutical Preparations |x standards |
| 650 | 2 | 2 | |a Quality Control |
| 650 | 2 | 2 | |a International Cooperation |
| 650 | 2 | |a Drug Industry |0 https://id.nlm.nih.gov/mesh/D004345 | |
| 650 | 6 | |a Industrie pharmaceutique |x Qualité |x Contrôle. | |
| 650 | 6 | |a Industrie pharmaceutique. | |
| 650 | 6 | |a Qualité |x Contrôle. | |
| 650 | 6 | |a Coopération internationale. | |
| 650 | 7 | |a quality control. |2 aat | |
| 650 | 7 | |a BUSINESS & ECONOMICS |x Industries |x General. |2 bisacsh | |
| 650 | 7 | |a Quality control |2 fast | |
| 650 | 7 | |a International cooperation |2 fast | |
| 650 | 7 | |a Fraud |x Prevention |2 fast | |
| 650 | 7 | |a Pharmaceutical industry |2 fast | |
| 650 | 7 | |a Pharmaceutical industry |x Quality control |2 fast | |
| 700 | 1 | |a Buckley, Gillian J., |e editor. |1 https://id.oclc.org/worldcat/entity/E39PCjqWbJbjtPFJQFrfRKC38K |0 http://id.loc.gov/authorities/names/no2012106161 | |
| 700 | 1 | |a Gostin, Lawrence O. |q (Lawrence Ogalthorpe), |e editor. |1 https://id.oclc.org/worldcat/entity/E39PBJjXj3gcXYGf6Rhy8Ggh73 |0 http://id.loc.gov/authorities/names/n77008863 | |
| 758 | |i has work: |a Countering the problem of falsified and substandard drugs (Text) |1 https://id.oclc.org/worldcat/entity/E39PCGDkgHvByMFcj4WwCqRhH3 |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Online version: |a Institute of Medicine (U.S.). Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products. |t Countering the problem of falsified and substandard drugs. |d Washington, D.C. : National Academies Press, 2013 |z 9780309269391 |w (OCoLC)850372447 |
| 856 | 1 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=867887 |3 Volltext | |
| 856 | 1 | |l CBO01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=867887 |3 Volltext | |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH36561345 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL3564286 | ||
| 938 | |a ebrary |b EBRY |n ebr10863743 | ||
| 938 | |a EBSCOhost |b EBSC |n 867887 | ||
| 938 | |a YBP Library Services |b YANK |n 11864774 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn839275199 |
|---|---|
| _version_ | 1813903607029825536 |
| adam_text | |
| any_adam_object | |
| author2 | Buckley, Gillian J. Gostin, Lawrence O. (Lawrence Ogalthorpe) |
| author2_role | edt edt |
| author2_variant | g j b gj gjb l o g lo log |
| author_GND | http://id.loc.gov/authorities/names/no2012106161 http://id.loc.gov/authorities/names/n77008863 |
| author_corporate | Institute of Medicine (U.S.). Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products |
| author_corporate_role | aut |
| author_facet | Buckley, Gillian J. Gostin, Lawrence O. (Lawrence Ogalthorpe) Institute of Medicine (U.S.). Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products |
| author_sort | Institute of Medicine (U.S.). Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | H - Social Science |
| callnumber-label | HD9665 |
| callnumber-raw | HD9665.5 .I578 2013 |
| callnumber-search | HD9665.5 .I578 2013 |
| callnumber-sort | HD 49665.5 I578 42013 |
| callnumber-subject | HD - Industries, Land Use, Labor |
| collection | ZDB-4-EBA |
| contents | Introduction -- The effects of falsified and substandard drugs -- The magnitude of the problem -- Causes of falsified and substandard drugs -- Weaknesses in the drug distribution chain -- Detection technology -- An international code of practice for falsified and substandard medicines. |
| ctrlnum | (OCoLC)839275199 |
| dewey-full | 338.4/76151 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/76151 |
| dewey-search | 338.4/76151 |
| dewey-sort | 3338.4 576151 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>07165cam a2200829 i 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn839275199</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20240705115654.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">130408t20132013dcuab obt 000 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">COO</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">COO</subfield><subfield code="d">GPM</subfield><subfield code="d">MMU</subfield><subfield code="d">AKU</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">UCNAP</subfield><subfield code="d">CUS</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">CUS</subfield><subfield code="d">VT2</subfield><subfield code="d">E7B</subfield><subfield code="d">N$T</subfield><subfield code="d">YDXCP</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">EBLCP</subfield><subfield code="d">OCLCO</subfield><subfield code="d">AGLDB</subfield><subfield code="d">MERUC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">ZCU</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">U3W</subfield><subfield code="d">OCLCA</subfield><subfield code="d">BUF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">GILDS</subfield><subfield code="d">STF</subfield><subfield code="d">VNS</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">VTS</subfield><subfield code="d">EZ9</subfield><subfield code="d">OCLCA</subfield><subfield code="d">ICG</subfield><subfield code="d">OCLCO</subfield><subfield code="d">CUY</subfield><subfield code="d">OCLCO</subfield><subfield code="d">REC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">AU@</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">WYU</subfield><subfield code="d">OCLCA</subfield><subfield code="d">LVT</subfield><subfield code="d">OCLCA</subfield><subfield code="d">S9I</subfield><subfield code="d">TKN</subfield><subfield code="d">DKC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">M8D</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">K6U</subfield><subfield code="d">OCLCA</subfield><subfield code="d">VLY</subfield><subfield code="d">OCLCO</subfield><subfield code="d">CUV</subfield><subfield code="d">VHC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCL</subfield><subfield code="d">OCLCO</subfield><subfield code="d">UKAHL</subfield><subfield code="d">OCLCL</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">UEJ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">880439886</subfield><subfield code="a">880598095</subfield><subfield code="a">929505330</subfield><subfield code="a">932320631</subfield><subfield code="a">961541600</subfield><subfield code="a">962566672</subfield><subfield code="a">1013281256</subfield><subfield code="a">1021249589</subfield><subfield code="a">1028757444</subfield><subfield code="a">1048158507</subfield><subfield code="a">1055345724</subfield><subfield code="a">1066010422</subfield><subfield code="a">1081203238</subfield><subfield code="a">1142730752</subfield><subfield code="a">1156364339</subfield><subfield code="a">1162554800</subfield><subfield code="a">1176019756</subfield><subfield code="a">1225734707</subfield><subfield code="a">1228558864</subfield><subfield code="a">1229699560</subfield><subfield code="a">1241869177</subfield><subfield code="a">1249222552</subfield><subfield code="a">1290089510</subfield><subfield code="a">1300664907</subfield><subfield code="a">1303326026</subfield><subfield code="a">1303518494</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309269407</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309269407</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9780309269391</subfield><subfield code="q">(paperback)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">0309269393</subfield><subfield code="q">(paperback)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)839275199</subfield><subfield code="z">(OCoLC)880439886</subfield><subfield code="z">(OCoLC)880598095</subfield><subfield code="z">(OCoLC)929505330</subfield><subfield code="z">(OCoLC)932320631</subfield><subfield code="z">(OCoLC)961541600</subfield><subfield code="z">(OCoLC)962566672</subfield><subfield code="z">(OCoLC)1013281256</subfield><subfield code="z">(OCoLC)1021249589</subfield><subfield code="z">(OCoLC)1028757444</subfield><subfield code="z">(OCoLC)1048158507</subfield><subfield code="z">(OCoLC)1055345724</subfield><subfield code="z">(OCoLC)1066010422</subfield><subfield code="z">(OCoLC)1081203238</subfield><subfield code="z">(OCoLC)1142730752</subfield><subfield code="z">(OCoLC)1156364339</subfield><subfield code="z">(OCoLC)1162554800</subfield><subfield code="z">(OCoLC)1176019756</subfield><subfield code="z">(OCoLC)1225734707</subfield><subfield code="z">(OCoLC)1228558864</subfield><subfield code="z">(OCoLC)1229699560</subfield><subfield code="z">(OCoLC)1241869177</subfield><subfield code="z">(OCoLC)1249222552</subfield><subfield code="z">(OCoLC)1290089510</subfield><subfield code="z">(OCoLC)1300664907</subfield><subfield code="z">(OCoLC)1303326026</subfield><subfield code="z">(OCoLC)1303518494</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">HD9665.5</subfield><subfield code="b">.I578 2013</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">QV 773</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">BUS</subfield><subfield code="x">070000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">338.4/76151</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="110" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.).</subfield><subfield code="b">Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products,</subfield><subfield code="e">author.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2014180450</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Countering the problem of falsified and substandard drugs /</subfield><subfield code="c">Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Board on Global Health ; Gillian J. Buckley and Lawrence O. Gostin, editors ; Institute of Medicine of the National Academies.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, D.C. :</subfield><subfield code="b">National Academies Press,</subfield><subfield code="c">[2013]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xxiv, 351 pages) :</subfield><subfield code="b">illustrations (chiefly color), color maps</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">data file</subfield><subfield code="2">rda</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">"The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines"--Publisher's description.</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Introduction -- The effects of falsified and substandard drugs -- The magnitude of the problem -- Causes of falsified and substandard drugs -- Weaknesses in the drug distribution chain -- Detection technology -- An international code of practice for falsified and substandard medicines.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English.</subfield></datafield><datafield tag="536" ind1=" " ind2=" "><subfield code="a">Supported by the National Academy of Sciences and the U.S. Food and Drug Administration</subfield><subfield code="b">HHSF22301024T</subfield><subfield code="g">25</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Online resource; title from resource home page (National Academies Press, viewed June 12, 2013).</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical industry.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical industry</subfield><subfield code="x">Quality control.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Fraud</subfield><subfield code="x">Prevention.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Quality control.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85109440</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">International cooperation.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85067385</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Counterfeit Drugs</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Fraud</subfield><subfield code="x">prevention & control</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Drug Contamination</subfield><subfield code="x">prevention & control</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Pharmaceutical Preparations</subfield><subfield code="x">standards</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Quality Control</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">International Cooperation</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Drug Industry</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D004345</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Industrie pharmaceutique</subfield><subfield code="x">Qualité</subfield><subfield code="x">Contrôle.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Industrie pharmaceutique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Qualité</subfield><subfield code="x">Contrôle.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Coopération internationale.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">quality control.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BUSINESS & ECONOMICS</subfield><subfield code="x">Industries</subfield><subfield code="x">General.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Quality control</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">International cooperation</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Fraud</subfield><subfield code="x">Prevention</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industry</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industry</subfield><subfield code="x">Quality control</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buckley, Gillian J.,</subfield><subfield code="e">editor.</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCjqWbJbjtPFJQFrfRKC38K</subfield><subfield code="0">http://id.loc.gov/authorities/names/no2012106161</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gostin, Lawrence O.</subfield><subfield code="q">(Lawrence Ogalthorpe),</subfield><subfield code="e">editor.</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PBJjXj3gcXYGf6Rhy8Ggh73</subfield><subfield code="0">http://id.loc.gov/authorities/names/n77008863</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Countering the problem of falsified and substandard drugs (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCGDkgHvByMFcj4WwCqRhH3</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Online version:</subfield><subfield code="a">Institute of Medicine (U.S.). Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products.</subfield><subfield code="t">Countering the problem of falsified and substandard drugs.</subfield><subfield code="d">Washington, D.C. : National Academies Press, 2013</subfield><subfield code="z">9780309269391</subfield><subfield code="w">(OCoLC)850372447</subfield></datafield><datafield tag="856" ind1="1" ind2=" "><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=867887</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="1" ind2=" "><subfield code="l">CBO01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=867887</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH36561345</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL3564286</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr10863743</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">867887</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">11864774</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-ocn839275199 |
| illustrated | Illustrated |
| indexdate | 2024-10-25T16:21:22Z |
| institution | BVB |
| institution_GND | http://id.loc.gov/authorities/names/n2014180450 |
| isbn | 9780309269407 0309269407 |
| language | English |
| oclc_num | 839275199 |
| open_access_boolean | |
| owner | MAIN |
| owner_facet | MAIN |
| physical | 1 online resource (xxiv, 351 pages) : illustrations (chiefly color), color maps |
| psigel | ZDB-4-EBA |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | National Academies Press, |
| record_format | marc |
| spelling | Institute of Medicine (U.S.). Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, author. http://id.loc.gov/authorities/names/n2014180450 Countering the problem of falsified and substandard drugs / Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Board on Global Health ; Gillian J. Buckley and Lawrence O. Gostin, editors ; Institute of Medicine of the National Academies. Washington, D.C. : National Academies Press, [2013] ©2013 1 online resource (xxiv, 351 pages) : illustrations (chiefly color), color maps text txt rdacontent computer c rdamedia online resource cr rdacarrier data file rda "The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines"--Publisher's description. Includes bibliographical references. Introduction -- The effects of falsified and substandard drugs -- The magnitude of the problem -- Causes of falsified and substandard drugs -- Weaknesses in the drug distribution chain -- Detection technology -- An international code of practice for falsified and substandard medicines. English. Supported by the National Academy of Sciences and the U.S. Food and Drug Administration HHSF22301024T 25 Online resource; title from resource home page (National Academies Press, viewed June 12, 2013). Pharmaceutical industry. Pharmaceutical industry Quality control. Fraud Prevention. Quality control. http://id.loc.gov/authorities/subjects/sh85109440 International cooperation. http://id.loc.gov/authorities/subjects/sh85067385 Counterfeit Drugs Fraud prevention & control Drug Contamination prevention & control Pharmaceutical Preparations standards Quality Control International Cooperation Drug Industry https://id.nlm.nih.gov/mesh/D004345 Industrie pharmaceutique Qualité Contrôle. Industrie pharmaceutique. Qualité Contrôle. Coopération internationale. quality control. aat BUSINESS & ECONOMICS Industries General. bisacsh Quality control fast International cooperation fast Fraud Prevention fast Pharmaceutical industry fast Pharmaceutical industry Quality control fast Buckley, Gillian J., editor. https://id.oclc.org/worldcat/entity/E39PCjqWbJbjtPFJQFrfRKC38K http://id.loc.gov/authorities/names/no2012106161 Gostin, Lawrence O. (Lawrence Ogalthorpe), editor. https://id.oclc.org/worldcat/entity/E39PBJjXj3gcXYGf6Rhy8Ggh73 http://id.loc.gov/authorities/names/n77008863 has work: Countering the problem of falsified and substandard drugs (Text) https://id.oclc.org/worldcat/entity/E39PCGDkgHvByMFcj4WwCqRhH3 https://id.oclc.org/worldcat/ontology/hasWork Online version: Institute of Medicine (U.S.). Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products. Countering the problem of falsified and substandard drugs. Washington, D.C. : National Academies Press, 2013 9780309269391 (OCoLC)850372447 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=867887 Volltext CBO01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=867887 Volltext |
| spellingShingle | Countering the problem of falsified and substandard drugs / Introduction -- The effects of falsified and substandard drugs -- The magnitude of the problem -- Causes of falsified and substandard drugs -- Weaknesses in the drug distribution chain -- Detection technology -- An international code of practice for falsified and substandard medicines. Pharmaceutical industry. Pharmaceutical industry Quality control. Fraud Prevention. Quality control. http://id.loc.gov/authorities/subjects/sh85109440 International cooperation. http://id.loc.gov/authorities/subjects/sh85067385 Counterfeit Drugs Fraud prevention & control Drug Contamination prevention & control Pharmaceutical Preparations standards Quality Control International Cooperation Drug Industry https://id.nlm.nih.gov/mesh/D004345 Industrie pharmaceutique Qualité Contrôle. Industrie pharmaceutique. Qualité Contrôle. Coopération internationale. quality control. aat BUSINESS & ECONOMICS Industries General. bisacsh Quality control fast International cooperation fast Fraud Prevention fast Pharmaceutical industry fast Pharmaceutical industry Quality control fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85109440 http://id.loc.gov/authorities/subjects/sh85067385 https://id.nlm.nih.gov/mesh/D004345 |
| title | Countering the problem of falsified and substandard drugs / |
| title_auth | Countering the problem of falsified and substandard drugs / |
| title_exact_search | Countering the problem of falsified and substandard drugs / |
| title_full | Countering the problem of falsified and substandard drugs / Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Board on Global Health ; Gillian J. Buckley and Lawrence O. Gostin, editors ; Institute of Medicine of the National Academies. |
| title_fullStr | Countering the problem of falsified and substandard drugs / Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Board on Global Health ; Gillian J. Buckley and Lawrence O. Gostin, editors ; Institute of Medicine of the National Academies. |
| title_full_unstemmed | Countering the problem of falsified and substandard drugs / Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Board on Global Health ; Gillian J. Buckley and Lawrence O. Gostin, editors ; Institute of Medicine of the National Academies. |
| title_short | Countering the problem of falsified and substandard drugs / |
| title_sort | countering the problem of falsified and substandard drugs |
| topic | Pharmaceutical industry. Pharmaceutical industry Quality control. Fraud Prevention. Quality control. http://id.loc.gov/authorities/subjects/sh85109440 International cooperation. http://id.loc.gov/authorities/subjects/sh85067385 Counterfeit Drugs Fraud prevention & control Drug Contamination prevention & control Pharmaceutical Preparations standards Quality Control International Cooperation Drug Industry https://id.nlm.nih.gov/mesh/D004345 Industrie pharmaceutique Qualité Contrôle. Industrie pharmaceutique. Qualité Contrôle. Coopération internationale. quality control. aat BUSINESS & ECONOMICS Industries General. bisacsh Quality control fast International cooperation fast Fraud Prevention fast Pharmaceutical industry fast Pharmaceutical industry Quality control fast |
| topic_facet | Pharmaceutical industry. Pharmaceutical industry Quality control. Fraud Prevention. Quality control. International cooperation. Counterfeit Drugs Fraud prevention & control Drug Contamination prevention & control Pharmaceutical Preparations standards Quality Control International Cooperation Drug Industry Industrie pharmaceutique Qualité Contrôle. Industrie pharmaceutique. Qualité Contrôle. Coopération internationale. quality control. BUSINESS & ECONOMICS Industries General. Quality control International cooperation Fraud Prevention Pharmaceutical industry Pharmaceutical industry Quality control |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=867887 |
| work_keys_str_mv | AT instituteofmedicineuscommitteeonunderstandingtheglobalpublichealthimplicationsofsubstandardfalsifiedandcounterfeitmedicalproducts counteringtheproblemoffalsifiedandsubstandarddrugs AT buckleygillianj counteringtheproblemoffalsifiedandsubstandarddrugs AT gostinlawrenceo counteringtheproblemoffalsifiedandsubstandarddrugs |